Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMARIN CORP PLC\UKAMRN · Entity 5970 | EVP, Chief Scientific Officer | July 01, 2026 | July 15, 2026 |
| Viracta Therapeutics, Inc.SNSS · Entity 85616 | Director | June 30, 2020 | July 01, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMARIN CORP PLC\UK
Report date July 01, 2026 · Filed July 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary SharesSEC Table I · non-derivative | Direct | 42,680 |
Last balance in matching sequence
After 2026-07-01 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-07-01 · Exercise / conversion · Acquired 3,688 · Balance 44,567 F1: Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change. F2: On January 10, 2025, the Reporting Person was granted 7,376 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2020 Stock Incentive Plan (the "Plan"). The shares subject to this grant shall vest over eighteen months, with 50% to vest on January 2, 2026 and the remaining balance to vest on July 1, 2026. F3: Not applicable. Row 2 · 2026-07-01 · Tax withholding · Disposed 1,887 · Balance 42,680 F1: Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change. F4: Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-07-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-01 · Grant · Acquired 3,688 · Balance 0 F5: Each RSU represents a contingent right to receive twenty Ordinary Shares or cash in lieu thereof at the Issuer's discretion. F1: Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change. F2: On January 10, 2025, the Reporting Person was granted 7,376 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2020 Stock Incentive Plan (the "Plan"). The shares subject to this grant shall vest over eighteen months, with 50% to vest on January 2, 2026 and the remaining balance to vest on July 1, 2026. F3: Not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change.
F2: On January 10, 2025, the Reporting Person was granted 7,376 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2020 Stock Incentive Plan (the "Plan"). The shares subject to this grant shall vest over eighteen months, with 50% to vest on January 2, 2026 and the remaining balance to vest on July 1, 2026.
F3: Not applicable.
F4: Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities.
F5: Each RSU represents a contingent right to receive twenty Ordinary Shares or cash in lieu thereof at the Issuer's discretion.
Viracta Therapeutics, Inc.
Report date June 30, 2020 · Filed July 01, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.26 · Expires 2030-06-30 | Direct | 60,000 |
Reported balance
After 2020-06-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-30 · Grant · Acquired 60,000 · Balance 60,000 F1: The option shall vest and become exercisable in twelve (12) equal monthly installments over a one (1) year period following the date of grant subject to the Reporting Person's continuous service on the Board through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest and become exercisable in twelve (12) equal monthly installments over a one (1) year period following the date of grant subject to the Reporting Person's continuous service on the Board through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 31, 2017 Filed Feb 2, 2017 22:06 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | Tax withholdingOrdinary Shares | 70,236 | $2.97 | $208,600.92 |
DisclosureSEC source: 0001209191-17-007167 · doc4.xml · nonDerivative · entry 4 Ketchum Steven B · CIK 0001289884 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,276 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F6 · kind: Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities. Read SEC document |
| January 31, 2017 Filed Feb 2, 2017 22:06 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | Exercise / conversionOrdinary Shares | 26,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-007167 · doc4.xml · nonDerivative · entry 3 Ketchum Steven B · CIK 0001289884 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,512 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F5 · shares: On February 1, 2016, the Reporting Person was granted 80,000 RSUs under the Amarin Corporation plc 2011 Stock Incentive Plan. These RSUs vest in three equal installments on each of January 31, 2017, January 31, 2018 and January 31, 2019. The first vesting event occurred on January 31, 2017. F3 · price: Not applicable. Read SEC document |
| January 31, 2017 Filed Feb 2, 2017 22:06 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | Exercise / conversionOrdinary Shares | 60,938 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-007167 · doc4.xml · nonDerivative · entry 2 Ketchum Steven B · CIK 0001289884 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F4 · shares: On February 2, 2015, the Reporting Person was granted 182,813 RSUs under the Amarin Corporation plc 2011 Stock Incentive Plan. These RSUs vest in three equal installments on each of January 31, 2016, January 31, 2017 and January 31, 2018. The second vesting event occurred on January 31, 2017. F3 · price: Not applicable. Read SEC document |
| January 31, 2017 Filed Feb 2, 2017 22:06 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | Exercise / conversionOrdinary Shares | 56,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-007167 · doc4.xml · nonDerivative · entry 1 Ketchum Steven B · CIK 0001289884 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,907 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · shares: On January 8, 2014, the Reporting Person was granted 169,500 restricted stock units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan. These RSUs vest in three equal installments on each of January 31, 2015, January 31, 2016 and January 31, 2017. The third and final vesting event occurred on January 31, 2017. F3 · price: Not applicable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.